CN115557900A - 一种3-取代哒嗪衍生物的合成方法 - Google Patents
一种3-取代哒嗪衍生物的合成方法 Download PDFInfo
- Publication number
- CN115557900A CN115557900A CN202211410587.4A CN202211410587A CN115557900A CN 115557900 A CN115557900 A CN 115557900A CN 202211410587 A CN202211410587 A CN 202211410587A CN 115557900 A CN115557900 A CN 115557900A
- Authority
- CN
- China
- Prior art keywords
- reaction
- derivative
- mmol
- pyridazine
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-substituted pyridazine Chemical class 0.000 title claims abstract description 41
- 238000010189 synthetic method Methods 0.000 title abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 156
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000002904 solvent Substances 0.000 claims abstract description 48
- 239000003054 catalyst Substances 0.000 claims abstract description 39
- 229910052786 argon Inorganic materials 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 238000001953 recrystallisation Methods 0.000 claims abstract description 6
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 6
- 238000010025 steaming Methods 0.000 claims abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 62
- 239000010948 rhodium Substances 0.000 claims description 49
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 150000004892 pyridazines Chemical class 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052703 rhodium Inorganic materials 0.000 claims description 7
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000007789 sealing Methods 0.000 abstract description 29
- 238000010898 silica gel chromatography Methods 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 150000003283 rhodium Chemical class 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 238000005481 NMR spectroscopy Methods 0.000 description 55
- 239000000047 product Substances 0.000 description 44
- 239000003208 petroleum Substances 0.000 description 37
- 239000003480 eluent Substances 0.000 description 36
- 238000004896 high resolution mass spectrometry Methods 0.000 description 29
- 238000000746 purification Methods 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 11
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- YICPBKWYZXFJNB-UHFFFAOYSA-N 3-chloro-1h-pyridazin-6-one Chemical compound OC1=CC=C(Cl)N=N1 YICPBKWYZXFJNB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- TVPRCLHSULCNLV-UHFFFAOYSA-N pyridazin-3-one Chemical compound O=C1C=CC=N[N]1 TVPRCLHSULCNLV-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- RWDZPWHMUXKPMN-UHFFFAOYSA-N 3,4-dichloro-1h-pyridazin-6-one Chemical compound ClC1=CC(=O)NN=C1Cl RWDZPWHMUXKPMN-UHFFFAOYSA-N 0.000 description 1
- XLAKVMDAMKGUET-UHFFFAOYSA-N 3-bromo-1h-pyridazin-6-one Chemical compound BrC=1C=CC(=O)NN=1 XLAKVMDAMKGUET-UHFFFAOYSA-N 0.000 description 1
- MTBWLDQCTOFHKW-UHFFFAOYSA-N 3-iodo-1h-pyridazin-6-one Chemical compound IC=1C=CC(=O)NN=1 MTBWLDQCTOFHKW-UHFFFAOYSA-N 0.000 description 1
- QZWIXLPWMGHDDD-UHFFFAOYSA-N 3-methyl-1h-pyridazin-6-one Chemical compound CC1=CC=C(O)N=N1 QZWIXLPWMGHDDD-UHFFFAOYSA-N 0.000 description 1
- IJUIPRDMWWBTTQ-UHFFFAOYSA-N 3-phenyl-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(C=2C=CC=CC=2)=N1 IJUIPRDMWWBTTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 238000006208 aza-Diels-Alder reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- OFCCYDUUBNUJIB-UHFFFAOYSA-N n,n-diethylcarbamoyl chloride Chemical compound CCN(CC)C(Cl)=O OFCCYDUUBNUJIB-UHFFFAOYSA-N 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- BIFDXOOJPDHKJH-UHFFFAOYSA-N piperidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCCC1 BIFDXOOJPDHKJH-UHFFFAOYSA-N 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/12—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于有机化工医药领域,涉及一种3‑取代哒嗪衍生物的合成方法。本发明以哒嗪‑3‑酮衍生物、芳基重氮化合物为原料,铑盐作为催化剂,再加入适量的溶剂,密封充氩气反应,在室温附近反应一定时间,反应结束后减压蒸去溶剂,产物经硅胶柱层析或重结晶分离得到目标产物;实现了3‑取代哒嗪衍生物的合成。本方法优点有:原料易得、底物适应性广、反应操作简单、反应效率高、原子经济性高,较符合绿色化学的要求。
Description
技术领域
本发明属于有机化工医药领域,涉及一种以哒嗪-3-酮衍生物和芳基重氮化合物为原料,金属铑盐为催化剂合成3-位是季碳中心取代的哒嗪衍生物。
背景技术
哒嗪是存在于许多已知药物或者新合成具有特殊生物药物活性先导分子中的关键母核(Chang,Y.,et al.J.Med.Chem.2019,62,8951–8952.Lu,Y.,etal.J.Med.Chem.2021,64,15214–15249.)。鉴于3-或6-取代哒嗪广泛分布于生物分子中(Chelini,A.,et al.M.J.Med.Chem.2017,60,5216–5221.Chelini,A.,etal.J.Med.Chem.2017,60,5216–5221.),具有非常特殊的生物活性,开发合成结构更复杂哒嗪衍生物的新方法,是其可被用于进一步进行高效药物筛选的前提。
取代哒嗪衍生物的合成最常用的方法主要是[4+2]环化反应(Wu,Q.,et al.RSCAdv.2019,9,21507-21512.Gao,Q.,et al.J.Org.Chem.2012,77,9865-9870.),该方法在合成出具有不同取代基的哒嗪衍生物方面已经取得了很大的成就。除此之外,也可以利用aza-Diels-Alder反应制备具有高区域选择性的取代吡嗪衍生物(Takayuki K.,etal.J.Org.Chem.2021,86,8926-8932),该方法具有很好的官能团相融性。尽管合成取代哒嗪衍生物的方法已经有很多,在常用的哒嗪原料上发生杂环环上的取代反应,实现3-烷基取代哒嗪的直接构建3-季碳中心难以实现。而哒嗪酮有两个氮,在3-位通过重排反应,存在选择性困难,直接引入季碳中心的方法目前还没有。
发明内容
针对背景技术中的问题,本发明提供了一种以哒嗪-3-酮衍生物和芳基重氮化合物为原料,金属铑盐为催化剂合成3-取代哒嗪衍生物的方法。本发明以哒嗪-3-酮衍生物和芳基重氮化合物为原料,在Rh的催化下,形成铑卡宾,进一步插入C=O后形成叶立德、随后进行环氧化和分子内重排,实现了使用廉价易得的原料合成3-位是季碳中心取代的哒嗪衍生物,该方法具有原料易得、底物适应性广、反应操作简单、反应效率高、原子经济性高等优点,较符合绿色化学的要求。特别是当使用手性铑催化剂时,可以得到具有中等对映选择性的手性3-取代哒嗪衍生物,极大的丰富了3-取代哒嗪衍生物的结构,高效构造该类结构的候选药物筛选分子库。
为了实现上述技术目的,采用的技术方案为:
本发明涉及一种3-取代的哒嗪衍生物的合成方法。反应首先加入哒嗪-3-酮衍生物,芳基重氮化合物以及铑催化剂,再加入适量的溶剂并用氩气保护,在20℃-35℃下反应15~60分钟,待反应结束后减压蒸去溶剂,以硅胶吸附,通过柱层析或混合溶剂重结晶分离得到目标产物;实现了以哒嗪-3-酮衍生物、芳基重氮化合物为原料,以铑盐为催化剂合成在3-位引入了季碳中心的3-取代哒嗪衍生物。所有产物其结构经1H NMR、13C NMR、HRMS和熔点确证。该反应投料的方式简便,底物适应性较广。
反应后用柱色谱分离方法提纯,以石油醚与乙酸乙酯的混合溶剂为洗脱剂或者以乙酸乙酯/石油醚体系为重结晶溶剂,对产物进行提纯以得到纯净的具有3-取代哒嗪衍生物产物。
具有3-取代哒嗪衍生物合成方法为:
所用的铑催化剂包括:Rh2(OAc)4、Rh2(PTTL)4、Rh2(esp)2、Rh2(Oct)4、Rh2(OPiv)4、Rh2(S-TFPTTL)4,其用量为哒嗪-3-酮衍生物摩尔数的0.5~2%,其中最佳催化剂为Rh2(OAc)4,最佳用量为哒嗪-3-酮化合物摩尔数的1%。
哒嗪-3-酮衍生物为下述结构:
芳基重氮化合物包括下述结构:
芳基重氮化合物的用量为哒嗪-3-酮衍生物用量的1~2.5当量。
先加入哒嗪-3-酮衍生物、芳基重氮化合物以及铑催化剂,再加入适量的溶剂,密封充氩气保护,在20℃-35℃下反应15~60分钟,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到产物,或者用EA/PE体系进行重结晶提纯。
所述反应溶剂为有机溶剂。具体的有机溶剂为二氯甲烷、正己烷、乙腈、乙醚、氯仿、甲苯、四氢呋喃、1,2-二氯乙烷中的一种。
哒嗪-3-酮衍生物在溶剂中的浓度为0.05~0.2mol/L。
本发明通过对哒嗪-3-酮衍生物和芳基重氮化合物为原料的结构设计,细致的反应条件筛选,在Rh的催化下合成了全新的3-取代哒嗪衍生物,可以高效在3-位引入了季碳中心,极大的丰富了3-取代哒嗪衍生物的结构。
有益效果:
1).反应原料易得,容易制备。
2).反应条件较为温和,特别是反应时间较短,效率高。
3).底物适应性广,产率中等至较高,部分产物有中等的对映选择性,高效在3-位引入了季碳中心,甚至手性季碳中心,极大的丰富了3-取代哒嗪衍生物的结构,为进一步的哒嗪衍生物药物筛选提供了分子库。
附图说明
图1为实施例1得到的3aa的1H-NMR(核磁氢谱);
图2为实施例1得到的3aa的13C-NMR(核磁碳谱);
图3为实施例1得到的3aa的HRMS(高分辨质谱)。
具体实施方式
下面结合实施例对本发明做进一步描述,但不限于此。
实施例1
向50ml反应管中加入3-羟基-6-氯哒嗪492mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1a 782mg,收率85%;m.p.70-72℃;1H NMR(300MHz,CDCl3)δ7.19(d,J=9.9Hz,1H),6.93(d,J=9.9Hz,1H),1.63(s,9H).13C NMR(75MHz,CDCl3)δ157.0,148.9,138.4,134.5,134.0,87.2,27.6.HRMS(ESI)m/z:[M+Na]+Calcd for C9H11ClN2NaO3253.0350;Found 253.0349.
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 68.9mg,收率82%;m.p.:135-137℃;1HNMR(400MHz,CDCl3)δ7.93(d,J=9.2Hz,1H),7.53-7.44(m,2H),7.40(d,J=9.2Hz,1H),7.37-7.28(m,3H),1.54(s,9H),1.51(s,9H).13C NMR(100MHz,CDCl3)δ167.4,159.5,156.2,152.1,137.3,130.0,128.8,128.7,127.5,126.2,84.4,83.9,83.6,27.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H26ClN2O5421.1525;Found 421.1529.
实施例1-1
放大反应:向100ml反应管中依次加入哒嗪-3-酮衍生物1a 690.0mg(3.0mmol),苯基重氮甲酯2a 1.31g(6.0mmol),随后加入催化剂Rh2(OAc)413.3mg(0.03mmol),60mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,重结晶纯化得到白色固体3aa 1.02g,收率81%。放大反应效果较好,拥有一定的工业生产价值。
实施例2
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(PTTL)42.4mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 26.9mg,收率32%。
实施例3
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(esp)21.5mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 57.1mg,收率68%。
实施例4
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(Oct)41.4mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 58.8mg,收率70%。
实施例5
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a65.4mg(0.3mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 17.6mg,收率21%。
实施例6
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.44mg(0.001mmol),4mL DCM。密封充氩气反应。反应在30℃下反应1h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 24.4mg,收率29%。
实施例7
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)41.76mg(0.004mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 47.1mg,收率56%。
实施例8
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL正己烷。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 36.1mg,收率43%。
实施例9
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL乙醚。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3aa 15.1mg,收率18%。
实施例10
向50ml反应管中加入3-羟基-6-溴哒嗪776mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1b 630mg,收率63%;m.p.:52-54℃;1H NMR(400MHz,CDCl3)δ7.25(d,J=9.6Hz,1H),6.82(d,J=9.6Hz,1H),1.63(s,9H).13C NMR(100MHz,CDCl3)δ156.9,149.0,137.2,133.6,127.5,87.2,27.6.HRMS(ESI)m/z:[M+Na]+Calcd for C9H11BrN2NaO3296.9845;Found 296.9847.
向反应管中依次加入哒嗪-3-酮衍生物1b 54.8mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ba 81.7mg,收率88%;m.p.:158-160℃;1HNMR(300MHz,CDCl3)δ7.81(d,J=9.0Hz,1H),7.54(d,J=9.0Hz,1H),7.51-7.42(m,2H),7.38-7.24(m,3H),1.54(s,9H),1.51(s,9H).13C NMR(75MHz,CDCl3)δ167.3,159.7,152.1,147.7,137.2,130.8,129.7,128.8,128.7,126.2,84.4,83.9,83.6,27.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H26BrN2O5465.1020,Found 465.1022.
实施例11
向50ml反应管中加入3-羟基-5,6-二氯哒嗪656mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1c528mg,收率50%;m.p.:79-81℃;1H NMR(400MHz,CDCl3)δ7.12(s,1H),1.63(s,9H).13C NMR(100MHz,CDCl3)δ156.2,148.2,140.4,137.4,131.2,87.7,27.6.HRMS(ESI)m/z:[M+Na]+Calcd for C9H10Cl2N2NaO3286.9961;Found 286.9959.
向反应管中依次加入哒嗪-3-酮衍生物1c 52.8mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到黄色油3ca66.3mg,收率73%;1H NMR(400MHz,CDCl3)δ8.15(s,1H),7.56-7.44(m,2H),7.40-7.28(m,3H),1.54(s,9H),1.51(s,9H).13C NMR(100MHz,CDCl3)δ167.2,160.1,154.8,152.1,137.0,136.9,129.4,129.0,128.9,126.0,84.2,83.9,83.8,27.7.HRMS(ESI)m/z:[M+H]+Calcd for C21H25Cl2N2O5455.1135;Found455.1138.
实施例12
向50ml反应管中加入3-羟基-6-氯哒嗪1.0g(7.7mmol),二甲氨基甲酰氯1.65g(15.4mmol),K2CO32.7 g(19.3mmol),nBu4NHSO426.2 mg(0.077mmol),20mL DCM,反应在室温下反应24h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1d 870mg,收率56%;m.p.:68-70℃;1H NMR(300MHz,CDCl3)δ7.63(d,J=9.0Hz,1H),7.46(d,J=9.0Hz,1H),3.17(s,3H),3.04(s,3H).13C NMR(75MHz,CDCl3)δ161.4,154.4,152.7,131.0,124.5,36.8,36.7.HRMS(ESI)m/z:[M+H]+Calcd forC7H9ClN3O 202.0378;Found 202.0378.
向反应管中依次加入哒嗪-3-酮衍生物1d 40.2mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到黄色油3da29.7mg,收率38%;1H NMR(400MHz,CDCl3)δ7.44-7.33(m,5H),7.18(d,J=9.6Hz,1H),6.95(d,J=9.6Hz,1H),3.01(s,3H),2.48(s,3H),1.53(s,9H).13C NMR(100MHz,CDCl3)δ165.1,163.7,159.7,136.2,133.8,132.3,132.2,129.4,128.7,128.1,84.0,82.2,39.4,37.7,27.8.HRMS(ESI)m/z:[M+H]+Calcd forC19H23ClN3O4392.1372;Found 392.1373.
实施例13
向50ml反应管中加入3-羟基-6-碘哒嗪888mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到黄色油状物1e 219mg,收率17%;1H NMR(400MHz,CDCl3)δ7.36(d,J=9.6Hz,1H),6.62(d,J=9.6Hz,1H),1.63(s,9H).13C NMR(100MHz,CDCl3)δ157.0,142.7,142.0,132.8,131.5,87.2,27.7.HRMS(ESI)m/z:[M+Na]+Calcd for C9H11IN2NaO3344.9707;Found 344.9706.
向反应管中依次加入哒嗪-3-酮衍生物1e 64.4mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ea86.0mg,收率84%;m.p.:186-188℃.1H NMR(300MHz,CDCl3)δ7.74(d,J=9.0Hz,1H),7.60(d,J=9.0Hz,1H),7.52-7.44(m,2H),7.38-7.26(m,3H),1.54(s,9H),1.51(s,9H).13C NMR(100MHz,CDCl3)δ167.3,159.7,152.1,137.3,136.5,128.8,128.7,128.6,126.2,124.7,84.5,83.9,83.6,27.78,27.77.HRMS(ESI)m/z:[M+H]+Calcd for C21H26IN2O5513.0881;Found 513.0885.
实施例14
向50ml反应管中加入3-羟基-6-苯基哒嗪688mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1f588mg,收率54%;m.p.:51-53℃.1H NMR(400MHz,CDCl3)δ7.84-7.78(m,2H),7.67(d,J=9.6Hz,1H),7.48-7.42(m,3H),7.01(d,J=9.6Hz,1H),1.67(s,9H).13C NMR(100MHz,CDCl3)δ158.1,150.4,144.6,134.0,132.2,131.2,130.0,129.0,126.3,86.5,27.7.HRMS(ESI)m/z:[M+Na]+Calcd for C15H16N2NaO3295.1053;Found 295.1054.
向反应管中依次加入哒嗪-3-酮衍生物1f54.4 mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到无色油状物3fa 74.9mg,收率81%;1H NMR(400MHz,CDCl3)δ8.07-7.99(m,3H),7.75(d,J=9.2Hz,1H),7.62-7.54(m,2H),7.51-7.40(m,3H),7.37-7.23(m,3H),1.54(s,9H),1.52(s,9H).13C NMR(75MHz,CDCl3)δ167.6,159.0,158.3,152.2,137.9,136.1,130.0,129.0,128.51,128.47,127.6,127.2,126.3,123.5,84.7,83.5,83.4,27.8.HRMS(ESI)m/z:[M+H]+Calcd for C27H31N2O5463.2227;Found 463.2233.
实施例15
向50ml反应管中加入3-羟基-6-氯哒嗪1.0g(7.7mmol),二乙氨基甲酰氯2.1g(15.4mmol),K2CO32.7 g(19.3mmol),nBu4NHSO426.2 mg(0.077mmol),20mL DCM,反应在室温下反应24h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到无色油状物1g 500mg,收率28%;1H NMR(400MHz,CDCl3)δ7.61(d,J=9.0Hz,1H),7.47(d,J=9.0Hz,1H),3.52(q,J=7.2Hz,2H),3.41(q,J=7.2Hz,2H),1.30(t,J=7.2Hz,3H),1.22(t,J=7.2Hz,3H).13C NMR(100MHz,CDCl3)δ161.5,154.4,152.1,130.9,124.5,42.5,42.3,14.2,13.1.HRMS(ESI)m/z:[M+H]+Calcd forC9H13ClN3O2230.0691;Found 230.0691.
向反应管中依次加入哒嗪-3-酮衍生物1g 45.8mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到黄色油状物3ga 21.8mg,收率26%;1H NMR(400MHz,CDCl3)δ7.41-7.28(m,5H),7.23(d,J=9.6Hz,1H),6.98(d,J=9.6Hz,1H),3.60-3.41(m,1H),3.35-3.16(m,1H),3.01-2.72(m,2H),1.48(s,9H),1.16(t,J=7.2Hz,3H),0.30(t,J=6.8Hz,3H).13C NMR(75MHz,CDCl3)δ165.2,164.0,159.7,136.7,133.9,132.4,132.1,129.1,128.1,127.6,83.6,83.1,42.8,40.5,27.8,11.6,11.2.HRMS(ESI)m/z:[M+H]+Calcdfor C21H27ClN3O4420.1685;Found 420.1684.
实施例16
向50ml反应管中加入3-羟基-6-氯哒嗪1.0g(7.7mmol),1-哌啶酰氯2.3g(15.4mmol),K2CO32.7 g(19.3mmol),nBu4NHSO426.2 mg(0.077mmol),20mL DCM,反应在室温下反应24h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到白色固体1h 800mg,收率43%;m.p.:85-87℃;1H NMR(400MHz,CDCl3)δ7.60(d,J=9.2Hz,1H),7.45(d,J=9.2Hz,1H),3.75-3.61(m,2H),3.59-3.47(m,2H),1.75-1.55(m,6H).13C{1H}NMR(100MHz,CDCl3)δ161.5,154.4,151.5,130.9,124.5,45.9,45.4,25.8,25.4,24.0.HRMS(ESI)m/z:[M+H]+Calcd for C10H13ClN3O2242.0691;Found242.0688.
向反应管中依次加入哒嗪-3-酮衍生物1h 48.2mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到黄色油状物3ha 37.1mg,收率43%;1H NMR(300MHz,CDCl3)δ7.44-7.30(m,5H),7.22(d,J=9.6Hz,1H),6.96(d,J=9.6Hz,1H),3.74-3.47(m,2H),3.00-2.77(m,2H),1.49(s,9H),1.49-1.34(m,4H),1.06-0.87(m,1H),0.80-0.56(m,1H).13C NMR(75MHz,CDCl3)δ164.9,164.2,163.9,159.6,136.4,133.8,132.3,129.2,128.3,127.7,83.7,82.8,48.6,44.8,27.8,25.3,24.1,24.0.HRMS(ESI)m/z:[M+H]+Calcdfor C22H27ClN3O4432.1685;Found 432.1687.
实施例17
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2b94.4mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ab 57.0mg,收率65%;m.p.:132-134℃;1HNMR(300MHz,CDCl3)δ7.95(d,J=9.3Hz,1H),7.57-7.46(m,2H),7.44(d,J=9.0Hz,1H),7.11-6.95(m,2H),1.53(s,9H),1.50(s,9H).13C NMR(75MHz,CDCl3)δ167.1,162.7(d,J=247.5Hz),159.6,156.3,151.9,133.2(d,J=3.8Hz),129.7,128.3(d,J=8.3Hz),127.6,115.6(d,J=21.8Hz),84.0,83.9,83.8,27.7.19F NMR(282MHz,CDCl3)δ-112.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H25ClFN2O5439.1431;Found 439.1434.
实施例18
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2c92.8mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ac 54.7mg,收率63%;m.p.:134-136℃;1HNMR(300MHz,CDCl3)δ7.90(d,J=9.3Hz,1H),7.42-7.31(m,3H),7.13(d,J=8.1Hz,2H),2.30(s,3H),1.54(s,9H),1.51(s,9H).13C NMR(75MHz,CDCl3)δ167.5,159.5,156.1,152.2,138.8,134.4,130.0,129.4,127.4,126.1,84.4,83.8,83.5,27.8,21.1.HRMS(ESI)m/z:[M+H]+Calcd for C22H28ClN2O5435.1681;Found 435.1684.
实施例19
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2d100.8mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ad 69.9mg,收率77%;m.p.:106-108℃;1HNMR(300MHz,CDCl3)δ7.96(d,J=9.2Hz,1H),7.58-7.53(m,1H),7.45(d,J=9.2Hz,1H),7.42-7.35(m,1H),7.31-7.25(m,2H),1.53(s,9H),1.50(s,9H).13C NMR(75MHz,CDCl3)δ166.8,159.4,156.4,151.8,139.1,134.7,129.9,129.6,129.0,127.7,126.6,124.4,84.2,84.0,83.8,27.7.HRMS(ESI)m/z:[M+H]+Calcd for C21H25Cl2N2O5455.1135;Found455.1135.
实施例20
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2e94.4mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ae 64.8mg,收率74%;m.p.:134-136℃;1HNMR(400MHz,CDCl3)δ7.97(d,J=9.2Hz,1H),7.83-7.72(m,1H),7.45(d,J=9.2Hz,1H),7.36-7.28(m,1H),7.22-7.13(m,1H),7.05-6.94(m,1H),1.51(s,9H),1.49(s,9H).13C NMR(100MHz,CDCl3)δ166.2,159.03,159.0(d,J=248.0Hz),156.4,151.7,130.9(d,J=8.0Hz),129.9(d,J=2.0Hz),129.3(d,J=2.0Hz),127.4,125.3(d,J=11.0Hz),124.4(d,J=3.0Hz),116.6,116.4,84.1,83.8,82.4,27.71,27.68.19F NMR(282MHz,CDCl3)δ-110.3.HRMS(ESI)m/z:[M+H]+Calcd for C21H25ClFN2O5439.1431;Found 439.1434.
实施例21
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2f114.4mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3af79.1 mg,收率81%;m.p.:160-162℃;1HNMR(400MHz,CDCl3)δ7.98(d,J=9.1Hz,1H),7.69(d,J=2.0Hz,1H),7.48(d,J=9.1Hz,1H),7.44-7.32(m,2H),1.53(s,9H),1.49(s,9H).13C NMR(75MHz,CDCl3)δ166.4,159.5,156.5,151.6,137.3,133.1,132.9,130.4,129.3,128.5,127.9,125.7,84.4,84.2,83.4,27.7.HRMS(ESI)m/z:[M+H]+Calcd for C21H24Cl3N2O5489.0745;Found 489.0749.
实施例22
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2g100.8mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体3ag 50.0mg,收率55%;m.p.:160-162℃;1HNMR(400MHz,CDCl3)δ7.94(d,J=9.2Hz,1H),7.49-7.43(m,2H),7.41(d,J=9.2Hz,1H),7.36-7.25(m,8H),5.34(d,J=12.4Hz,1H),5.25(d,J=12.4Hz,1H),1.42(s,9H).13C NMR(100MHz,CDCl3)δ168.6,159.4,156.4,152.0,136.8,134.7,129.6,129.0,128.8,128.7,128.54,128.52,127.8,126.2,84.4,84.1,68.2,27.6.HRMS(ESI)m/z:[M+H]+Calcd forC24H24ClN2O5455.1368;Found 455.1369.
实施例23
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2h87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到黄色油3ah73.9mg,收率88%;1H NMR(400MHz,CDCl3)δ7.96(d,J=9.1Hz,1H),7.53-7.46(m,2H),7.43(d,J=9.1Hz,1H),7.38-7.28(m,3H),4.40-4.18(m,2H),1.70-1.58(m,2H),1.51(s,9H),1.40-1.28(m,2H),0.89(t,J=7.6Hz,3H).13CNMR(100MHz,CDCl3)δ168.8,159.5,156.3,152.1,137.0,129.7,129.0,128.7,127.7,126.2,84.4,83.9,66.4,30.4,27.7,19.0,13.6.HRMS(ESI)m/z:[M+H]+Calcd forC21H26ClN2O5421.1525;Found 421.1528.
实施例24
向反应管中依次加入哒嗪-3-酮衍生物1a 46.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(S-TFPTTL)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/5]纯化得到白色固体(R)-3aa 59.7mg,收率71%,76%ee;m.p.:135-137℃;HPLC(IA,n-hexane/i-PrOH=80/20,flow rate=1.0mL/min,I=225nm)tR=4.45min(major),5.38min(minor),76%ee.[α]D 20:-11.6(c=0.50,CHCl3;76%ee).1HNMR(400MHz,CDCl3)δ7.93(d,J=9.2Hz,1H),7.53-7.44(m,2H),7.40(d,J=9.2Hz,1H),7.37-7.28(m,3H),1.54(s,9H),1.51(s,9H).13C NMR(100MHz,CDCl3)δ167.4,159.5,156.2,152.1,137.3,130.0,128.8,128.7,127.5,126.2,84.4,83.9,83.6,27.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H26ClN2O5421.1525;Found 421.1529.
对比例1
向50ml反应管中加入3-羟基-6-甲基哒嗪440mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O 1.1g(5.2mmol),20mL THF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到无色油状物588mg,收率70%;1H NMR(400MHz,CDCl3)δ7.10(d,J=9.6Hz,1H),6.84(d,J=9.6Hz,1H),2.36(s,3H),1.63(s,9H).13C NMR(100MHz,CDCl3)δ158.0,150.7,145.0,134.2,131.7,86.2,27.6,20.9.HRMS(ESI):calculated for C10H15N2NaO3[M+Na]+:233.0897;Found:233.0894.
向反应管中依次加入哒嗪-3-酮衍生物42.0mg(0.2mmol),苯基重氮化合物2a87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后检测反应发现哒嗪-3-酮衍生物完全不反应,无产物。
对比例2
向50ml反应管中加入哒嗪-3-酮384mg(4.0mmol),DMAP 48.8mg(0.4mmol),Boc2O1.1g(5.2mmol),20mLTHF,反应在30℃下反应4h,反应结束后减压蒸去溶剂,产物经硅胶柱层析[洗脱剂:V(乙酸乙酯)/V(石油醚)=1/3]纯化得到棕色固体306mg,收率39%;1H NMR(400MHz,CDCl3)δ7.81(dd,J=3.6,1.6Hz,1H),7.20(dd,J=9.6,3.6Hz,1H),6.94(dd,J=10.0,1.6Hz,1H),1.64(s,9H).13C NMR(100MHz,CDCl3)δ158.5,150.2,136.5,132.2,131.8,86.6,27.6.HRMS(ESI):calculated for C9H12N2NaO3[M+Na]+:219.0740;Found:219.0739.
向反应管中依次加入哒嗪-3-酮39.2mg(0.2mmol),苯基重氮化合物2a 87.2mg(0.4mmol),随后加入催化剂Rh2(OAc)40.88mg(0.002mmol),4mL DCM。密封充氩气反应。反应在30℃下反应0.5h,反应结束后检测反应发现反应很杂,生成很多副产物,原料转化率大概在50%,但产物产率<5%。产率太低,没有拿到产物。
Claims (8)
5.如权利要求2所述的3-取代哒嗪衍生物的合成方法,其特征在于:芳基重氮化合物的用量为哒嗪-3-酮衍生物用量的1~2.5当量。
6.如权利要求2所述的3-取代哒嗪衍生物的合成方法,其特征在于:所用铑催化剂为Rh2(OAc)4、Rh2(PTTL)4、Rh2(esp)2、Rh2(Oct)4、Rh2(OPiv)4、Rh2(S-TFPTTL)4中的一种,用量为哒嗪-3-酮衍生物摩尔数的0.5~2%。
7.如权利要求2所述的3-取代哒嗪衍生物的合成方法,其特征在于:所用溶剂为二氯甲烷、正己烷、乙腈、乙醚、氯仿、甲苯、四氢呋喃、1,2-二氯乙烷中的一种,哒嗪-3-酮衍生物在溶剂中的浓度为0.05~0.2mol/L。
8.如权利要求2所述的3-取代哒嗪衍生物的合成方法,其特征在于:所用反应温度为20℃~35℃搅拌反应15~60分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211410587.4A CN115557900B (zh) | 2022-11-11 | 2022-11-11 | 一种3-取代哒嗪衍生物的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211410587.4A CN115557900B (zh) | 2022-11-11 | 2022-11-11 | 一种3-取代哒嗪衍生物的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115557900A true CN115557900A (zh) | 2023-01-03 |
CN115557900B CN115557900B (zh) | 2024-03-15 |
Family
ID=84770106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211410587.4A Active CN115557900B (zh) | 2022-11-11 | 2022-11-11 | 一种3-取代哒嗪衍生物的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115557900B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293554A (en) * | 1980-02-21 | 1981-10-06 | American Cyanamid Company | Method of treating asthma |
CN102617443A (zh) * | 2012-02-29 | 2012-08-01 | 华东师范大学 | 一种光学活性吲哚衍生物及其合成方法和应用 |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN110240568A (zh) * | 2019-04-01 | 2019-09-17 | 兰州大学 | 三取代哒嗪类衍生物及其制备方法 |
CN111533697A (zh) * | 2020-05-07 | 2020-08-14 | 成都大学 | 4-氨基哒嗪酮类化合物及其制备方法 |
CN111848526A (zh) * | 2020-07-10 | 2020-10-30 | 南京工业大学 | 多取代1,4-二氢哒嗪和哒嗪类衍生物及其合成方法 |
CN113248480A (zh) * | 2021-05-12 | 2021-08-13 | 常州大学 | 一种呋喃卡宾化学选择性和对映选择性插入2-吡啶酮或3-哒嗪酮n-h键的方法 |
-
2022
- 2022-11-11 CN CN202211410587.4A patent/CN115557900B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293554A (en) * | 1980-02-21 | 1981-10-06 | American Cyanamid Company | Method of treating asthma |
CN102617443A (zh) * | 2012-02-29 | 2012-08-01 | 华东师范大学 | 一种光学活性吲哚衍生物及其合成方法和应用 |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN110240568A (zh) * | 2019-04-01 | 2019-09-17 | 兰州大学 | 三取代哒嗪类衍生物及其制备方法 |
CN111533697A (zh) * | 2020-05-07 | 2020-08-14 | 成都大学 | 4-氨基哒嗪酮类化合物及其制备方法 |
CN111848526A (zh) * | 2020-07-10 | 2020-10-30 | 南京工业大学 | 多取代1,4-二氢哒嗪和哒嗪类衍生物及其合成方法 |
CN113248480A (zh) * | 2021-05-12 | 2021-08-13 | 常州大学 | 一种呋喃卡宾化学选择性和对映选择性插入2-吡啶酮或3-哒嗪酮n-h键的方法 |
Non-Patent Citations (1)
Title |
---|
熊俊如等: ""3,6-双取代哒嗪的合成和介晶性"", 《应用化学》, vol. 20, no. 11, pages 1088 - 1092 * |
Also Published As
Publication number | Publication date |
---|---|
CN115557900B (zh) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109912606B (zh) | 一种嘧啶并吲唑类化合物的合成方法 | |
CN114920775B (zh) | 一种轴手性双吲哚催化剂及其合成方法与应用 | |
CN110511175B (zh) | 一种1,6-烯炔类化合物与偶氮烷基腈的自由基环化反应方法 | |
Abe et al. | C4 pictet–spengler reactions for the synthesis of core structures in hyrtiazepine alkaloids | |
CN113214129B (zh) | 一种磺酰自由基引发的1,6-二烯类化合物碘化/磺酰化反应方法 | |
CN107602577A (zh) | 手性桥环骨架羟吲哚螺哌啶类化合物及其合成方法 | |
Mahmud et al. | An intramolecular azomethine ylide–alkene cycloaddition approach to pyrrolo [3, 2-c] quinolines-synthesis of a C2-truncated martinelline model | |
JP2013170151A (ja) | インドール‐3−トリフロン類の直接的製造法及びインドールトリフロン誘導体 | |
Zhao et al. | Pyrrolo [2, 3-b] pyridine derivatives as potent Bruton’s tyrosine kinase inhibitors | |
Hutskalova et al. | Control over stereogenic N–N axes by Pd-catalyzed 5-endo-hydroaminocyclizations | |
CN110467553A (zh) | 一种基于1,6-烯炔类化合物硝化/环化反应的新方法 | |
CN114105978A (zh) | 一种氧化吲哚类化合物及其制备方法和应用 | |
CN112209915A (zh) | 一种空气氧化n-吡啶吲哚啉类化合物的方法 | |
Singh et al. | Molecular iodine enabled generation of iminyl radicals from oximes: A facile route to imidazo [1, 2-a] pyridines and its regioselective C-3 sulfenylated products from simple pyridines | |
Potowski et al. | Biology-oriented synthesis of benzopyrano [3, 4-c] pyrrolidines | |
CN115557900B (zh) | 一种3-取代哒嗪衍生物的合成方法 | |
CN109651271B (zh) | 一种3-叔丁基-n-甲基喹喔啉-2(1h)-酮化合物的合成方法 | |
CN111320634A (zh) | 一种乙酰氧取代的吡咯并[2,3-d]嘧啶衍生物的制备方法 | |
CN114014805B (zh) | 三氟甲基化2,4-喹啉二酮类化合物的制备方法 | |
Hasník et al. | Synthesis of (purin-6-yl) acetates and 6-(2-hydroxyethyl) purines via cross-couplings of 6-chloropurines with the Reformatsky reagent | |
CN108976198B (zh) | 一种3-(4-吡啶)吲哚类化合物的合成方法 | |
CN115232066A (zh) | 一种光催化烯烃合成1,2-烷基芳基乙烷化合物的方法 | |
CN107513056A (zh) | 一种含四氢呋喃基团的喹啉类化合物的合成方法 | |
CN113735851A (zh) | 一种可见光促进3-苯基咪唑并[1,5-α]吡啶-1-腈的合成方法 | |
CN113896732A (zh) | 抗癌药物卡马替尼的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |